Although aromatase immunohistochemistry is not used as an indicator of aromatase inhibition in patients with ER-positive breast cancer, it can be used to determine the local synthesis of estrogen in several cancer types (Miki et al. 2007, Miki et al. 2010, Grindstad et al. 2016). Here, CYP19A1 is linked to breast carcinoma.